Additionally, agents targeting ghrelin directly, such as inhibitors of ghrelin O-acyltransferase, are being investigated as potential therapeutics for ghrelin-related diseases, including obesity and type 2 diabetes [116]. Here, MBOAT4 is linked to obesity due to melanocortin 4 receptor deficiency.